Palatin Technologies Inc
LSE:0KF3

Watchlist Manager
Palatin Technologies Inc Logo
Palatin Technologies Inc
LSE:0KF3
Watchlist
Price: 1.0889 USD -2.94%
Market Cap: 29.9B USD

Palatin Technologies Inc
Investor Relations

Palatin Technologies Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies to address unmet medical needs in various health conditions, particularly in women's health and sexual dysfunction. The company is primarily known for its lead product candidate, Vyleesi (bremelanotide injection), which was approved by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). This groundbreaking therapy offers a novel approach to a condition that has traditionally been underserved, highlighting Palatin’s commitment to improving quality of life for its patients. With a robust pipeline of other potential treatments, the company is positioning itself to be a significant player in the biotech sector.

Investors will find Palatin appealing not only for its unique product offerings but also for its strategic partnerships and collaborations that enhance its research capabilities and market reach. The company has established relationships with key healthcare organizations, enabling it to conduct pivotal clinical trials and expand its product visibility. Additionally, leadership at Palatin utilizes a disciplined, value-investing approach, ensuring that resources are allocated wisely towards projects with solid scientific backing and commercial potential. As the company advances its portfolio, it aims to create long-term shareholder value while addressing critical areas of health, making it a compelling opportunity for those looking to invest in the future of biopharmaceutical innovations.

Show more
Loading

Earnings Calls

2024 Q3
Nov 12, 2024
Show Transcript
Previous
Next
TeraWulf reports challenges while positioning for growth with new power capabilities.
2024 Q3
Nov 12, 2024

In Q3 2024, TeraWulf self-mined 555 bitcoins, down 21% from the previous quarter, leading to a 24% revenue decline to $27.1 million. They recently sold their 25% stake in Nautilus for $85 million, streamlining operations. The improved power cost per mined bitcoin rose to $30,448. Looking ahead, they expect Q4 production costs of $59,000 per bitcoin and anticipate significant growth in high-performance computing. They have $400 million allocated for infrastructure upgrades and a $200 million stock buyback, having already repurchased $115 million in shares. This strategy aims to leverage their clean energy resources effectively amid increasing demand.

Show Full Analysis

Management

Dr. Carl Spana Ph.D.
Co-Founder, President, CEO & Director
No Bio Available
Mr. Stephen T. Wills CPA, MST
CFO, COO, Executive VP, Treasurer & Secretary
No Bio Available
Burns McClellan
Vice President of Investor Relations
No Bio Available
Mr. Stephen A. Slusher Esq.
Chief Legal Officer
No Bio Available
Dr. Michael B. Raizman M.D.
Chief Medical Officer
No Bio Available
Mr. James E. Hattersley
Senior Vice President of Business Development
No Bio Available
Mr. John Dodd Ph.D.
Senior Vice President of Preclinical Development
No Bio Available
Mr. Robert Jordan
Senior Vice President of Program Operations
No Bio Available

Contacts

Address
NEW JERSEY
Cranbury
4B Cedar Brook Drive
Contacts
+16094952200.0
www.palatin.com